Biogen banks on government coverage to restart stalled Alzheimer's drug sales

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. III
6. TTEC
7. DAL
8. AWK
9. GZDIF
10. ATNI

Go back to Biogen banks on government coverage to restart stalled Alzheimer's drug sales

Biogen (BIIB) PT Lowered to $390 at Oppenheimer

October 20, 2021 6:05 PM EDT

Oppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $390.00 (from $450.00) while maintaining an Outperform rating.

The analyst commented, "Bolstered by a 3Q top- and bottom-line beat, BIIB outlined a number of steps to support the Aduhelm launch but deferred... More

Biogen (BIIB) Stock Edges Higher on Strong Earnings, Sales of New Alzheimer Drug Just $300k

October 20, 2021 9:00 AM EDT

Biogen (NASDAQ: BIIB) stock is up about 1.5% in pre-open Wednesday after the company reported better-than-expected Q3 EPS.

BIIB reported Q3 EPS of $4.77 to beat the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.

As far as full-year guidance is concerned, Biogen projects FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61.... More

Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst

October 20, 2021 8:21 AM EDT

Earlier today, Biogen (NASDAQ: BIIB) reported Q3 results: EPS of $4.77, $0.66 better than the analyst estimate of $4.11; revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.

The company also updated its full-year guidance: EPS of $18.85-$19.35, versus the consensus of $18.61; FY2021... More